Skip to Content

16 Results Found

  • Article
  • Open Access
5 Citations
3,545 Views
9 Pages

Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis

  • Michelle L. Tas,
  • Lisa W. Dootjes,
  • Marta Fiocco,
  • Ronald R. de Krijger and ,
  • Miranda P. Dierselhuis,
  • Natasha K. A. van Eijkelenburg,
  • Martine van Grotel,
  • Kathelijne C. J. M. Kraal,
  • Annemarie M. L. Peek and
  • Max M. van Noesel
  • + 6 authors+ 1 author

30 September 2021

Background: Anti-GD2 based immunotherapy has improved overall (OS) and event free survival (EFS) for high-risk neuroblastoma (HR-NBL) patients. Here, we evaluate the long-term efficacy of anti-GD2 immunotherapy in combination with isotretinoin, GM-CS...

(This article belongs to the Special Issue Hot Topics in Neuro-Oncology)
  • Article
  • Open Access
3 Citations
2,689 Views
22 Pages

Affinity Affects the Functional Potency of Anti-GD2 Antibodies by Target-Mediated Drug Disposition

  • Sascha Troschke-Meurer,
  • Maxi Zumpe,
  • Peter Moritz Ahrenberg,
  • Torsten Ebeling and ,
  • Nikolai Siebert,
  • Piotr Grabarczyk and
  • Holger N. Lode
  • + 2 authors+ 0 author

30 July 2025

Background/Objectives: High-risk neuroblastoma patients are treated with approved anti-ganglioside GD2 antibodies of moderate (dinutuximab beta; DB) and higher binding affinity (naxitamab; NAXI). We evaluated the functional potency of DB compared to...

(This article belongs to the Special Issue Precision Medicine and Targeted Therapies in Neuroblastoma)
  • Review
  • Open Access
18 Citations
5,676 Views
24 Pages

Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma

  • Chenkai Mao,
  • Maria Poimenidou and
  • Brian T. Craig

17 August 2024

Neuroblastoma (NBL) cells highly express disialoganglioside GD2, which is restricted and weakly expressed in selected healthy cells, making it a desirable target of immunotherapy. Over the past two decades, application of dinutuximab, an anti-GD2 mon...

(This article belongs to the Special Issue Combination Immunotherapy for Cancer Treatment)
  • Article
  • Open Access
45 Citations
9,967 Views
17 Pages

RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype

  • Maxim Sorokin,
  • Irina Kholodenko,
  • Daniel Kalinovsky,
  • Tatyana Shamanskaya and ,
  • Igor Doronin,
  • Dmitry Konovalov,
  • Aleksei Mironov,
  • Denis Kuzmin,
  • Daniil Nikitin and
  • Roman Kholodenko
  • + 7 authors+ 2 authors

The tumor-associated ganglioside GD2 represents an attractive target for cancer immunotherapy. GD2-positive tumors are more responsive to such targeted therapy, and new methods are needed for the screening of GD2 molecular tumor phenotypes. In this w...

(This article belongs to the Section Cancer Biology and Oncology)
  • Article
  • Open Access
8 Citations
4,646 Views
15 Pages

Combination administration is becoming a popular strategy in current cancer immunotherapy to enhance tumor response to ICIs. Recently, a peptide drug, a protein–protein interaction inhibitor (PPI), that disrupts the β-catenin/Bcl9 interact...

(This article belongs to the Special Issue Drug Repurposing and Delivery Systems for Immunotherapy)
  • Article
  • Open Access
1 Citations
3,160 Views
17 Pages

Evaluation of a Combinatorial Immunotherapy Regimen That Can Cure Mice Bearing MYCN-Driven High-Risk Neuroblastoma That Resists Current Clinical Therapy

  • Lauren Zebertavage,
  • Allison Schopf,
  • Megan Nielsen,
  • Joel Matthews and ,
  • Amy K. Erbe,
  • Taylor J. Aiken,
  • Sydney Katz,
  • Claire Sun,
  • Cole M. Witt and
  • Paul M. Sondel
  • + 6 authors+ 1 author

26 April 2024

Background: Incorporating GD2-targeting monoclonal antibody into post-consolidation maintenance therapy has improved survival for children with high-risk neuroblastoma. However, ~50% of patients do not respond to, or relapse following, initial treatm...

(This article belongs to the Special Issue High-Risk Neuroblastoma: New Clinical Insights and Challenges)
  • Article
  • Open Access
19 Citations
3,645 Views
19 Pages

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta

  • Nikolai Siebert,
  • Maxi Zumpe,
  • Christian Heinrich Schwencke,
  • Simon Biskupski and ,
  • Sascha Troschke-Meurer,
  • Justus Leopold,
  • Alexander Zikoridse and
  • Holger N. Lode
  • + 3 authors+ 0 author

23 June 2023

Immunotherapies against high-risk neuroblastoma (NB), using the anti-GD2 antibody (Ab) dinutuximab beta (DB), significantly improved patient survival. Ab-dependent cellular cytotoxicity (ADCC) is one of the main mechanisms of action and it is primari...

(This article belongs to the Special Issue Advances in Cancer Immunotherapy)
  • Case Report
  • Open Access
3 Citations
3,770 Views
6 Pages

Pulmonary Exacerbation of Undiagnosed Toxocariasis in Intensively-Treated High-Risk Neuroblastoma Patients

  • Szymon Janczar,
  • Monika Bulas,
  • Justyna Walenciak,
  • Dobromila Baranska and ,
  • Marek Ussowicz,
  • Wojciech Młynarski and
  • Beata Zalewska-Szewczyk
  • + 2 authors+ 0 author

5 October 2020

Toxocariasis is one of the most common zoonoses, with high seroprevalence in apparently healthy individuals. Neuroblastoma is an aggressive childhood cancer. The cure rates are improving due to dose-dense chemotherapy, progress in surgical practice,...

(This article belongs to the Section Pediatric Hematology & Oncology)
  • Article
  • Open Access
10 Citations
3,954 Views
11 Pages

Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments

  • Leah Klingel,
  • Nikolai Siebert,
  • Sascha Troschke-Meurer,
  • Maxi Zumpe and ,
  • Karoline Ehlert,
  • Stefanie Huber,
  • Hans Loibner,
  • Oliver Mutschlechner and
  • Holger N. Lode
  • + 4 authors+ 0 author

25 November 2022

(1) Background: High-risk neuroblastoma (HR-NB) is associated with a poor prognosis despite a multimodal high-intensity treatment regimen, including immunotherapy with anti-GD2 monoclonal antibodies (mAb). Here, we investigated the effects of an anti...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Review
  • Open Access
1,165 Views
28 Pages

24 May 2026

Desmoplastic small round cell tumor (DSRCT) is a rare and highly malignant tumor that mostly occurs in young males. Due to its extremely strong invasiveness and poor prognosis, the treatment of DSRCT remains a major challenge in current medical resea...

(This article belongs to the Special Issue Advances in Cancer Targeted Therapy)
  • Article
  • Open Access
20 Citations
5,285 Views
18 Pages

Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation - Design, Synthesis, and Cellular Studies

  • Katarzyna Kuncewicz,
  • Claire Battin,
  • Adam Sieradzan,
  • Agnieszka Karczyńska and ,
  • Marta Orlikowska,
  • Anna Wardowska,
  • Michał Pikuła,
  • Peter Steinberger,
  • Sylwia Rodziewicz-Motowidło and
  • Marta Spodzieja
  • + 5 authors+ 0 author

23 November 2020

One of the major current trends in cancer immunotherapy is the blockade of immune checkpoint proteins that negatively regulate the immune response. This has been achieved through antibodies blocking PD-1/PD-L1 and CTLA-4/CD80/CD86 interactions. Such...

(This article belongs to the Special Issue Cancer Immunotherapy Using Checkpoint Inhibitors: Future Directions 2.0)
  • Review
  • Open Access
13 Citations
4,881 Views
13 Pages

13 August 2024

Immunotherapy has emerged as an attractive option for patients with relapsed or refractory high-risk neuroblastoma (HRNB). Neuroblastoma (NB), a sympathetic nervous system cancer arising from an embryonic neural crest cell, is heterogeneous clinicall...

(This article belongs to the Special Issue High-Risk Neuroblastoma: New Clinical Insights and Challenges)
  • Article
  • Open Access
11 Citations
3,726 Views
18 Pages

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD2 Antibody Dinutuximab Beta

  • Nikolai Siebert,
  • Justus Leopold,
  • Maxi Zumpe,
  • Sascha Troschke-Meurer and ,
  • Simon Biskupski,
  • Alexander Zikoridse and
  • Holger N. Lode
  • + 2 authors+ 0 author

4 October 2022

Treatment of high-risk neuroblastoma (NB) patients with the anti-GD2 antibody (Ab) dinutuximab beta (DB) improves survival by 15%. Ab-dependent cellular cytotoxicity (ADCC) is the major mechanism of action and is primarily mediated by NK cells. Since...

(This article belongs to the Special Issue Tumor Immunology and Immunotherapy Resistance)
  • Review
  • Open Access
880 Views
39 Pages

Metabolic and Post-Translational Vulnerabilities of Glioblastoma: Disulfidptosis, Glycosylation, and Implications for CAR-T Therapy

  • Tadeusz Strózik,
  • Adrianna Rutkowska,
  • Tomasz Wasiak,
  • Damian Ciunowicz and ,
  • Piotr Rieske,
  • Natalia Szczepaniak and
  • Ewelina Stoczyńska-Fidelus
  • + 2 authors+ 0 author

15 June 2026

Glioblastoma (GB) remains one of the most therapy-resistant solid tumors, characterized by profound metabolic plasticity, intratumoral heterogeneity, and a highly immunosuppressive microenvironment. While immunotherapies such as chimeric antigen rece...

(This article belongs to the Special Issue Cell Death Mechanisms and Therapeutic Opportunities in Glioblastoma)
  • Article
  • Open Access
6 Citations
3,121 Views
15 Pages

Dinutuximab Beta for the Treatment of High-Risk Neuroblastoma: Data from the Hungarian Pediatric Oncology Network

  • Márk Hernádfői,
  • Márton Szabados,
  • Edit Brückner,
  • Ágnes Varga and ,
  • Péter Hauser,
  • Gábor Ottóffy,
  • Ágnes Vojcek,
  • Krisztina Csanádi,
  • Gabriella Kertész and
  • Miklós Garami
  • + 7 authors+ 2 authors

20 September 2025

Background/Objectives: The anti-GD2 monoclonal antibody dinutuximab beta has become standard of care maintenance therapy for high-risk neuroblastoma (HR-NB) in the first-line setting and is also approved in the relapsed/refractory setting. We present...

(This article belongs to the Section Oncology)
  • Article
  • Open Access
27 Citations
5,353 Views
12 Pages

Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes

  • Juan Pablo Muñoz,
  • Cristina Larrosa,
  • Saray Chamorro,
  • Sara Perez-Jaume and ,
  • Margarida Simao,
  • Nazaret Sanchez-Sierra,
  • Amalia Varo,
  • Maite Gorostegui,
  • Alicia Castañeda and
  • Jaume Mora
  • + 7 authors+ 2 authors

3 October 2023

Patients with high-risk neuroblastoma (HR-NB) who are unable to achieve a complete response (CR) to induction therapy have worse outcomes. We investigated the combination of humanized anti-GD2 mAb naxitamab (Hu3F8), irinotecan (I), temozolomide (T),...

(This article belongs to the Section Pediatric Oncology)